Table 2.
Stage I–III | rMBC | p value | |
---|---|---|---|
(n = 7328) | (n = 964) | ||
N (%) | N (%) | ||
Stage | |||
I | 4036 (55%) | 163 (17%) | < 0.001 |
II | 2688 (37%) | 447 (46%) | |
III | 604 (8%) | 354 (37%) | |
Age | |||
20–39 | 497 (7%) | 140 (15%) | < 0.001 |
40–49 | 1680 (23%) | 250 (26%) | |
50–69 | 3660 (50%) | 428 (44%) | |
70–79 | 1071 (15%) | 118 (12%) | |
80+ | 420 (6%) | 28 (3%) | |
Mean age (range and significance of F statistic) | 58 (21–94) | 54 (23–93) | < 0.001 |
Race | |||
White | 6267 (86%) | 842 (87%) | 0.142 |
Non-white | 1061 (14%) | 122 (13%) | |
Diagnosis year primary breast cancer | |||
1990–1998 | 1917 (26%) | 455 (47%) | < 0.001 |
(row totals) | (81%) | (19%) | |
1999–2004 | 2128 (29%) | 260 (27%) | |
(row totals) | (89%) | (11%) | |
2005–2011 | 3283 (45%) | 249 (26%) | |
(row totals) | (93%) | (7%) | |
Initial breast tumor detection method | |||
By patient or physician (symptomatic) | 3322 (46%) | 706 (74%) | < 0.001 |
By mammography | 3906 (54%) | 244 (26%) | |
Hormone receptor status at initial diagnosis (n = 8169) | |||
HR+ | 6182 (86%) | 703 (74%) | < 0.001 |
HER2 status at initial diagnosis (n = 5475)* | |||
HER2+ (HR− or HR+) | 690 (14%) | 80 (17%) | 0.07 |
HR/HER2 status at initial diagnosis (n = 5470)* | |||
HR+/HER2− | 3830 (77%) | 287 (60%) | < 0.001 |
HR+/HER2+ | 476 (10%) | 53 (11%) | |
HR−/HER2− | 475 (10%) | 108 (23%) | |
HR−/HER2+ | 214 (4%) | 27 (6%) | |
Histologic type primary breast tumor | |||
Ductal | 5924 (81%) | 780 (81%) | 0.005 |
Lobular | 672 (9%) | 113 (12%) | |
Lobular/ductal mixed | 336 (5%) | 37 (4%) | |
Other cancer | 396 (5%) | 34 (4%) | |
Nuclear grade initial primary breast tumor | |||
Low/intermediate | 4207 (60%) | 357 (41%) | < 0.001 |
High | 2802 (40%) | 530 (59%) | |
Histologic grade initial primary breast tumor | |||
Low/intermediate | 2492 (36%) | 196 (22%) | < 0.001 |
High | 4465 (64%) | 703 (78%) | |
Tumor size (mean, range, and significance of F statistic) | 1.98 cm (0.1–21 cm) | 3.67 cm (0.1–20 cm) | < 0.001 |
Number of positive lymph nodes (mean, range, and significance of F statistic) | 0.93 (0–44) | 4.44 (0–36) | < 0.001 |
*Trastuzumab FDA approval 1998, consistent HER2 testing began in 1999